Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3/2015

01-09-2015 | Clinical

The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review

Authors: Fernando Mendes, Cátia Domingues, Ricardo Teixo, Ana Margarida Abrantes, Ana Cristina Gonçalves, Inês Nobre-Gois, Miguel Jacobetty, Ana Bela Sarmento, Maria Filomena Botelho, Manuel Santos Rosa

Published in: Cancer and Metastasis Reviews | Issue 3/2015

Login to get access

Abstract

Diffuse large B cell lymphoma is recognized as a heterogeneous group of hematological malignancies; two main subtypes germinal center B and activated B cells are well defined although 15 % of patients remain with unclassifiable disease. R-CHOP treatment has proven to provide very effective results in limited or advanced stage of the disease. However, treatment solely involving R-CHOP submits the patient to possible chemotherapy-induced toxicities, which may be avoided with the use of radiotherapy. Patients with early stage localized disease or who are particularly unresponsive to chemotherapy may be more suitable for mixed modality treatment with R-CHOP and consolidative radiotherapy. Although radiotherapy is being slowly phased out by other treatment strategies including chemotherapy and therapeutic drugs, it is still a highly important method of treatment. The different forms of radiotherapy can be used alongside these “new-age” treatment strategies to further improve prognostic outcomes and overall survival rates. The establishment of radiotherapy as a treatment strategy provides a highly beneficial prognostic advantage in early stage, localized disease.
Literature
1.
2.
3.
4.
5.
6.
Tilly, H., Vitolo, U., Walewski, J., da Silva, M. G., Shpilberg, O., Andre, M., … Dreyling, M. (2012). Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(suppl_7), vii78–vii82. doi:10.​1093/​annonc/​mds273
7.
Morgan, G., Vornanen, M., Puitinen, J., Naukkarinen, A, Brincker, H., Olsen, J., … Cartwright, R. (1997). Changing trends in the incidence of non-Hodgkin’s lymphoma in Europe. Biomed Study Group. Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO, 8(Suppl 2), 49–54.
8.
Swerdlow SH, Campo E, Harris NL, E. Al. (2008). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. In I. A. for R. on C. Cancer (Ed.), Lyon.
9.
Kaminski, M. S., Coleman, C. N., Colby, T. V., Cox, R. S., & Rosenberg, S. A. (1986). Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Annals of Internal Medicine, 104(6), 747–756. Retrieved from http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​3518561.
10.
Monfardini, S., Banfi, A., Bonadonna, G., Rilke, F., Milani, F., Valagussa, P., & Lattuada, A. (1980). Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin’s lymphoma. International Journal of Radiation Oncology, Biology, Physics, 6(2), 125–134. doi:10.​1016/​0360-3016(80)90189-3.CrossRefPubMed
11.
Nissen, N. I., Ersbøll, J., Hansen, H. S., Walbom-Jørgensen, S., Pedersen-Bjergaard, J., Hansen, M. M., & Rygård, J. (1983). A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin’s lymphomas. Cancer, 52(1), 1–7. Retrieved from http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​6406037.
12.
Hudson, B., Hudson, G., Maclennan, K., Anderson, L., & Linch, D. (1994). Clinical stage-1 Non-Hodgkins-lymphoma—long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Bristish Journal of Cancer, 69, 1088–1093. Retrieved from http://​discovery.​ucl.​ac.​uk/​42259/​.
13.
Sabattini, E., Bacci, F., Sagramoso, C., & Pileri, S. A. (2010). WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica, 102(3), 83–87.PubMed
14.
15.
Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A, … Staudt, L.M. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403(February), 503–511. doi:10.​1038/​35000501.
16.
Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., … Staudt, L.M. (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346(25), 1937–1947. doi:10.​1056/​NEJMoa012914.
17.
Landberg, T.G., Håkansson, L.G., Möller, T.R., Mattsson, W.K., Landys, K.E., Johansson, B. G., … Dahl, O.G. (1979). CVP-remission-maintenance in stage I or II non-Hodgkin’s lymphomas: preliminary results of a randomized study. Cancer, 44(3), 831–838. Retrieved from http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​383273.
18.
Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., … Staudt, L.M. (2008). Stromal gene signatures in large-B-cell lymphomas. The New England Journal of Medicine, 359(22), 2313–2323. doi:10.​1056/​NEJMoa0802885.
19.
20.
21.
22.
23.
24.
Béguelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K., Rosen, M., … Melnick, A. (2013). EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell, 23(5), 677–692. doi:10.​1016/​j.​ccr.​2013.​04.​011.
25.
Caganova, M., Carrisi, C., Varano, G., Mainoldi, F., Zanardi, F., Germain, P. L., … Casola, S. (2013). Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. Journal of Clinical Investigation, 123(12), 5009–5022. doi:10.​1172/​JCI70626.
26.
Morin, R.D., Johnson, N. a, Severson, T.M., Mungall, A.J., An, J., Goya, R., … Marra, M.A. (2010). Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genetics, 42(2), 181–185. doi:10.​1038/​ng.​518.
27.
Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., & Copeland, R. A. (2010). Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 107(49), 20980–20985. doi:10.​1073/​pnas.​1012525107.PubMedCentralCrossRefPubMed
28.
Cerchietti, L.C., Ghetu, A.F., Zhu, X., Da Silva, G.F., Zhong, S., Matthews, M., … Melnick, A. (2010). A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell, 17(4), 400–411. doi:10.​1016/​j.​ccr.​2009.​12.​050.
29.
McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G.S., … Creasy, C.L. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 492(7427), 108–12. doi:10.​1038/​nature11606.
30.
Pfeifer, M., Grau, M., Lenze, D., Wenzel, S.S., Wolf, A., Wollert-Wulf, B., … Lenz, G. (2013). PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 110(30), 12420–5. doi:10.​1073/​pnas.​1305656110.
31.
Lenz, G., Wright, G.W., Emre, N.C.T., Kohlhammer, H., Dave, S.S., Davis, R.E., … Staudt, L.M. (2008). Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proceedings of the National Academy of Sciences of the United States of America, 105(36), 13520–13525. doi:10.​1073/​pnas.​0804295105.
32.
Iqbal, J., Meyer, P.N., Smith, L.M., Johnson, N.A., Vose, J.M., Greiner, T.C., … Chan, W.C. (2011). BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clinical Cancer Research, 17(24), 7785–7795. doi:10.​1158/​1078-0432.​CCR-11-0267.
33.
Souers, A.J., Leverson, J.D., Boghaert, E.R., Ackler, S.L., Catron, N.D., Chen, J., … Elmore, S.W. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine, 19(2), 202–8. doi:10.​1038/​nm.​3048.
34.
Lenz, G., Davis, R.E., Ngo, V.N., Lam, L., George, T.C., Wright, G.W., … Staudt, L.M. (2008). Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (New York, N.Y.), 319(5870), 1676–1679. doi:10.​1126/​science.​1153629.
35.
Compagno, M., Lim, W.K., Grunn, A., Nandula, S.V, Brahmachary, M., Shen, Q., … Pasqualucci, L. (2009). Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature, 459(7247), 717–721. doi:10.​1038/​nature07968.
36.
Kato, M., Sanada, M., Kato, I., Sato, Y., Takita, J., Takeuchi, K., … Ogawa, S. (2009). Frequent inactivation of A20 in B-cell lymphomas. Nature, 459(7247), 712–716. doi:10.​1038/​nature07969.
37.
Rimsza, L.M., LeBlanc, M.L., Unger, J.M., Miller, T.P., Grogan, T.M., Persky, D.O., … Gascoyne, R.D. (2008). Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood, 112(8), 3425–3433. doi:10.​1182/​blood-2008-02-137372.
38.
Meyer, P.N., Fu, K., Greiner, T.C., Smith, L.M., Delabie, J., Gascoyne, R.D., … Weisenburger, D.D. (2011). Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. Journal of Clinical Oncology, 29(2), 200–207. doi:10.​1200/​JCO.​2010.​30.​0368.
39.
Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., … Chan, W.C. (2004). Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103(1), 275–282. doi:10.​1182/​blood-2003-05-1545.
40.
De Jong, D., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W., Lee, A., … Weller, E. (2007). Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the Lunenburg lymphoma biomarker consortium. Journal of Clinical Oncology, 25(7), 805–812. doi:10.​1200/​JCO.​2006.​09.​4490.
41.
42.
Tilly, H., & Dreyling, M. (2010). Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: Official Journal of the European Society for Medical Oncology / ESMO, 21 Suppl 5(suppl_5), v172–v174. doi:10.​1093/​annonc/​mdq203.
43.
44.
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano Classification. Journal of Clinical Oncology, 32(27), 1–10. doi:10.​1200/​JCO.​2013.​54.​8800.CrossRef
45.
46.
Shipp, M.A., Harrigton, D.P., Anderson, J.R., Bonadonna, G., Brittinger, G., Cabanillhas, F., & Canellhos, G.P. (1993). A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. The New England Journal of Medicine, 329. doi:10.​1056/​NEJM199309303291​402.
47.
Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., … Connors, J.M. (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109(5), 1857–1861. doi:10.​1182/​blood-2006-08-038257.
48.
Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M., & Loeffler, M. (2010). Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28(14), 2373–2380. doi:10.​1200/​JCO.​2009.​26.​2493.CrossRefPubMed
49.
Zhou, Z., Sehn, L.H., Rademaker, A.W., Gordon, L.I., LaCasce, A.S., Crosby-Thompson, A., … Winter, J.N. (2014). An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 123(6), 837–842. doi:10.​1182/​blood-2013-09-524108.
50.
Müller, C., Murawski, N., Wiesen, M. H. J., Held, G., Poeschel, V., Zeynalova, S., … Reiser, M. (2012). The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood, 119(14), 3276–3284. doi:10.​1182/​blood-2011-09-380949.
51.
Maurer, M. J., Micallef, I. N. M., Cerhan, J. R., Katzmann, J. a., Link, B. K., Colgan, J. P., … Witzig, T. E. (2011). Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 29(12), 1620–1626. doi:10.​1200/​JCO.​2010.​29.​4413.
52.
Sehn, L.H., Scott, D.W., Chhanabhai, M., Berry, B., Ruskova, A., Berkahn, L., … Gascoyne, R.D. (2011). Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. Journal of Clinical Oncology, 29(11), 1452–1457. doi:10.​1200/​JCO.​2010.​33.​3419.
53.
Pfreundschuh, M., Ho, A.D., Cavallin-Stahl, E., Wolf, M., Pettengell, R., Vasova, I., … Kuhnt, E. (2008). Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group. The Lancet Oncology, 9(5), 435–444. doi:10.​1016/​S1470-2045(08)70078-0.
54.
Carson, K.R., Bartlett, N.L., McDonald, J.R., Luo, S., Zeringue, A., Liu, J., … Colditz, G.A. (2012). Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 30(26), 3217–3222. doi:10.​1200/​JCO.​2011.​39.​2100.
55.
Porrata, L.F., Ristow, K.M., Habermann, T.M., Witzig, T.E., Colgan, J.P., Inwards, D.J., … Markovic, S.N. (2014). Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leukemia & Lymphoma, 55(12), 2728–38. doi:10.​3109/​10428194.​2014.​893313.
56.
Wilcox, R.A, Ristow, K., Habermann, T.M., Inwards, D.J., Micallef, I.N. M., Johnston, P.B., … Porrata, L. (2011). The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 25(9), 1502–1509. doi:10.​1038/​leu.​2011.​112
57.
Drake, M. T., Maurer, M.J., Link, B.K., Habermann, T.M., Ansell, S.M., Micallef, I.N., … Cerhan, J.R. (2010). Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28(27), 4191–4198. doi:10.​1200/​JCO.​2010.​28.​6674.
58.
Hong, F., Habermann, T.M., Gordon, L.I., Hochster, H., Gascoyne, R.D., Morrison, V.A., … Kahl, B.S. (2014). The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Annals of Oncology, 25(3), 669–674. doi:10.​1093/​annonc/​mdt594.
59.
Persky, D.O., Unger, J.M., Spier, C.M., Stea, B., LeBlanc, M., McCarty, M.J., … Miller, T.P. (2008). Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. Journal of Clinical Oncology, 26(14), 2258–2263. doi:10.​1200/​JCO.​2007.​13.​6929.
60.
Phan, J., Mazloom, A., Medeiros, L.J., Zreik, T.G., Wogan, C., Shihadeh, F., … Dabaja, B.S. (2010). Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. Journal of Clinical Oncology, 28(27), 4170–4176. doi:10.​1200/​JCO.​2009.​27.​3441.
61.
Horning, S. J., Weller, E., Kim, K., Earle, J. D., O’Connell, M. J., Habermann, T. M., & Glick, J. H. (2004). Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group Study 1484. Journal of Clinical Oncology, 22(15), 3032–3038. doi:10.​1200/​JCO.​2004.​06.​088.CrossRefPubMed
62.
Zelenetz, A.D., Wierda, W.G., Abramson, J.S., Advani, R.H., Andreadis, C.B., Bartlett, N., … Naganuma, M. (2013). Non-Hodgkin’s lymphomas, version 1.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 11(3), 257–72; quiz 273. Retrieved from http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23486452.
63.
Miller, T.P., Dahlberg, S., Cassady, J.R., Adelstein, D.J., Spier, C.M., Grogan, T.M., … Fisher, R.I. (1998). Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. The New England Journal of Medicine, 339(1), 21–26. doi:10.​1056/​NEJM199807023390​104.
64.
65.
Maraldo, M. V., Aznar, M. C., Vogelius, I. R., Petersen, P. M., & Specht, L. (2013). Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma. International Journal of Radiation Oncology, Biology, Physics, 85(4), 1057–1065. doi:10.​1016/​j.​ijrobp.​2012.​08.​041.CrossRefPubMed
66.
Campbell, B. A., Connors, J. M., Gascoyne, R. D., Morris, W. J., Pickles, T., & Sehn, L. H. (2012). Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer, 118(17), 4156–4165. doi:10.​1002/​cncr.​26687.CrossRefPubMed
67.
Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., … Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346. doi:10.​1056/​NEJMoa011795.
68.
Feugier, P., Van Hoof, A, Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., … Coiffier, B. (2005). Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23(18), 4117–4126. doi:10.​1200/​JCO.​2005.​09.​131.
69.
Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., … Loeffler, M. (2008). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet Oncology, 9(2), 105–116. doi:10.​1016/​S1470-2045(08)70002-0.
70.
Maurer, M.J., Ghesquières, H., Jais, J.P., Witzig, T.E., Haioun, C., Thompson, C.A., … Cerhan, J.R. (2014). Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. Journal of Clinical Oncology, 32(10), 1066–1073. doi:10.​1200/​JCO.​2013.​51.​5866.
71.
Récher, C., Coiffier, B., Haioun, C., Molina, T.J., Fermé, C., Casasnovas, O., … Tilly, H. (2011). Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial. The Lancet, 378(9806), 1858–1867. doi:10.​1016/​S0140-6736(11)61040-4.
72.
André, M., Mounier, N., Leleu, X., Sonet, A., Brice, P., Henry-Amar, M., … Gisselbrecht, C. (2004). Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: A GELA cohort study on 2837 patients. Blood, 103(4), 1222–1228. doi:10.​1182/​blood-2003-04-1124.
73.
Cunningham, D., Hawkes, E.A., Jack, A., Qian, W., Smith, P., Mouncey, P., … Linch, D. (2013). Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. The Lancet, 381(9880), 1817–1826. doi:10.​1016/​S0140-6736(13)60313-X.
74.
Delarue, R., Tilly, H., Mounier, N., Petrella, T., Salles, G., Thieblemont, C., … Bosly, A. (2013). Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. The Lancet Oncology, 14(6), 525–533. doi:10.​1016/​S1470-2045(13)70122-0
75.
Gang, A.O., Strøm, C., Pedersen, M., d’Amore, F., Pedersen, L.M., Bukh, A., … Nully Brown, P. (2012). R-choep-14 improves overall survival in young high-risk patients with diffuse large b-cell lymphoma compared with r-chop-14. A population-based investigation from the danish lymphoma group. Annals of Oncology, 23(1), 147–153. doi:10.​1093/​annonc/​mdr058.
76.
Pfreundschuh, M., Kuhnt, E., Trümper, L., Österborg, A., Trneny, M., Shepherd, L., … Murawski, N. (2011). CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet Oncology, 12(11), 1013–1022. doi:10.​1016/​S1470-2045(11)70235-2.
77.
Wilson, W.H., Dunleavy, K., Pittaluga, S., Hegde, U., Grant, N., Steinberg, S.M., … Janik, J.E. (2008). Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. Journal of Clinical Oncology, 26(16), 2717–2724. doi:10.​1200/​JCO.​2007.​13.​1391.
78.
Wilson, W.H., Jung, S.H., Porcu, P., Hurd, D., Johnson, J., Eric Martin, S., … Hsi, E.D. (2012). A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica, 97(5), 758–765. doi:10.​3324/​haematol.​2011.​056531.
79.
Martinelli, G., Gigli, F., Calabrese, L., Ferrucci, P. F., Zucca, E., Crosta, C., … Moreno Gomez, H. (2009). Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. (IELSG 4). [corrected]. Leukemia & Lymphoma, 50(6), 925–931. doi:10.​1080/​1042819090291247​8.
80.
Bonnet, C., Fillet, G., Mounier, N., Ganem, G., Molina, T.J., Thiéblemont, C., … Reyes, F. (2007). CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. Journal of Clinical Oncology, 25(7), 787–792. doi:10.​1200/​JCO.​2006.​07.​0722.
81.
Ballonoff, A., Rusthoven, K.E., Schwer, A., McCammon, R., Kavanagh, B., Bassetti, M., … Rabinovitch, R. (2008). Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. International Journal of Radiation Oncology Biology Physics, 72(5), 1465–1471. doi:10.​1016/​j.​ijrobp.​2008.​02.​068.
82.
Ferreri, A.J., Dell’Oro, S., Reni, M., Ceresoli, G.L., Cozzarini, C., Ponzoni, M., & Villa, E. (2000). Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas. Oncology, 58(3), 219–226.
83.
Schlembach, P. J., Wilder, R. B., Tucker, S. L., Ha, C. S., Rodriguez, M. A., Hess, M. A., & Cox, J. D. (2000). Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. International Journal of Radiation Oncology Biology Physics, 48(4), 1107–1110. doi:10.​1016/​S0360-3016(00)00760-4.CrossRef
84.
Horwitz, S.M., Negrin, R.S., Blume, K.G., Breslin, S., Stuart, M.J., Stockerl-Goldstein, K.E., … Horning, S.J. (2004). Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood, 103(3), 777–783. doi:10.​1182/​blood-2003-04-1257.
85.
Shi, Z., Das, S., Okwan-Duodu, D., Esiashvili, N., Flowers, C., Chen, Z., … Khan, M.K. (2013). Patterns of failure in advanced stage diffuse large b-cell lymphoma patients after complete response to r-chop immunochemotherapy and the emerging role of consolidative radiation therapy. International Journal of Radiation Oncology Biology Physics, 86(3), 569–577. doi:10.​1016/​j.​ijrobp.​2013.​02.​007.
86.
Dorth, J. A., Prosnitz, L. R., Broadwater, G., Diehl, L. F., Beaven, A. W., Coleman, R. E., & Kelsey, C. R. (2012). Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. International Journal of Radiation Oncology Biology Physics, 84(3), 762–767. doi:10.​1016/​j.​ijrobp.​2011.​12.​067.CrossRef
87.
88.
Reyes, F., Lepage, E., Ganem, G., Molina, T.J., Brice, P., Coiffier, B., … Tilly, H. (2005). ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. The New England Journal of Medicine, 352(12), 1197–1205. doi:10.​1056/​NEJMoa042040.
89.
Lowry, L., Smith, P., Qian, W., Falk, S., Benstead, K., Illidge, T., … Hoskin, P. (2011). Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiotherapy and Oncology, 100(1), 86–92. doi:10.​1016/​j.​radonc.​2011.​05.​013.
90.
91.
92.
Juweid, M.E., Stroobants, S., Hoekstra, O.S., Mottaghy, F.M., Dietlein, M., Guermazi, A., … Cheson, B.D. (2007). Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. Journal of Clinical Oncology, 25(5), 571–578. doi:10.​1200/​JCO.​2006.​08.​2305.
93.
Mikhaeel, N. G., Hutchings, M., Fields, P. A., O’Doherty, M. J., & Timothy, A. R. (2005). FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Annals of Oncology, 16(June), 1514–1523. doi:10.​1093/​annonc/​mdi272.CrossRefPubMed
94.
Mikhaeel, N. G., Timothy, A. R., O’Doherty, M. J., Hain, S., & Maisey, M. N. (2000). 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma-comparison with CT. Leukemia & Lymphoma, 39(5-6), 543–553. doi:10.​3109/​1042819000911338​4.CrossRef
95.
Noordijk, E.M., Carde, P., Dupouy, N., Hagenbeek, A., Krol, A. D.G., Kluin-Nelemans, J.C., … Henry-Amar, M. (2006). Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 24(19), 3128–35. doi:10.​1200/​JCO.​2005.​05.​2746.
96.
Bonadonna, G., Bonfante, V., Viviani, S., Di Russo, A., Villani, F., & Valagussa, P. (2004). ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 22(14), 2835–2841. doi:10.​1200/​JCO.​2004.​12.​170.CrossRef
97.
Zwam, H. M. (2013). Involved nodal radiotherapy vs. involved field radiotherapy after chemotherapy in the treatment of early stage Hodgkin’s lymphoma. Journal of Cancer Therapy, 04(01), 271–279. doi:10.​4236/​jct.​2013.​41034.CrossRef
98.
Avilés, A., Delgado, S., Nambo, M. J., Alatriste, S., & Díaz-Maqueo, J. (1994). Adjuvant radiotherapy to sites of previous bulky disease in patients stage iv diffuse large cell lymphoma. International Journal of Radiation Oncology Biology Physics, 30(4), 799–803. doi:10.​1016/​0360-3016(94)90352-2.CrossRef
99.
Avilés, A., Neri, N., Delgado, S., Pérez, F., Nambo, M.J., Cleto, S., … Huerta-Guzmán, J. (2005). Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy. Medical oncology (Northwood, London, England), 22(4), 383–387. doi:10.​1385/​MO:​22:​4:​383.
100.
Avilés, A., Fernández, R., Pérez, F., Nambo, M. J., Neri, N., Talavera, A., … Cleto, S. (2004). Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improve outcome. Leukemia & Lymphoma, 45(7), 1385–1389. doi:10.​1080/​1042819041000166​7712.
101.
Held, G., Murawski, N., Ziepert, M., Fleckenstein, J., Poschel, V., Zwick, C., … Pfreundschuh, M. (2014). Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. Journal of Clinical Oncology, 32(11), 1112–1118. doi:10.​1200/​JCO.​2013.​51.​4505.
102.
Jerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999). Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood, 94(2), 429–433. Retrieved from http://​www.​bloodjournal.​org/​content/​94/​2/​429.​abstract.
103.
Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., … Verhoef, G. (2001). Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? Journal of Clinical Oncology, 19(2), 414–419. Retrieved from http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​11208833.
104.
Ramalingam, S.S., Kotsakis, A., Tarhini, A.A., Heron, D.E., Smith, R., Friedland, D., … Argiris, A. (2013). A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer, 81(3), 416–421. doi:10.​1016/​j.​lungcan.​2013.​06.​002.
105.
Barrington, S.F., Mikhaeel, N.G., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S.P., … Cheson, B.D. (2014). Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology, 32(27), 3048–3058. doi:10.​1200/​JCO.​2013.​53.​5229.
106.
Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., … Diehl, V. (2007). Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25(5), 579–586. doi:10.​1200/​JCO.​2006.​09.​2403.
107.
Juweid, M.E., Wiseman, G.A., Vose, J.M., Ritchie, J.M., Menda, Y., Wooldridge, J.E., … Cheson, B.D. (2005). Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. Journal of Clinical Oncology, 23(21), 4652–4661. doi:10.​1200/​JCO.​2005.​01.​891.
108.
Kamath, S. S., Marcus, R. B., Lynch, J. W., & Mendenhall, N. P. (1999). The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin’s lymphoma. International Journal of Radiation Oncology Biology Physics, 44(3), 563–568. doi:10.​1016/​S0360-3016(99)00051-6.CrossRef
109.
Bindra, R. S., & Yahalom, J. (2011). The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again. Expert Review of Anticancer Therapy, 11(9), 1367–1378. doi:10.​1586/​era.​11.​88.CrossRefPubMed
110.
Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., … Horning, S.J. (2006). Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24(19), 3121–3127. doi:10.​1200/​JCO.​2005.​05.​1003.
111.
Shenkier, T.N., Voss, N., Fairey, R., Gascoyne, R.D., Hoskins, P., Klasa, R., … Connors, J.M. (2002). Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. Journal of Clinical Oncology, 20(1), 197–204. doi:10.​1200/​JCO.​20.​1.​197.
112.
Peyrade, F., Jardin, F., Thieblemont, C., Thyss, A., Emile, J. F., Castaigne, S., … Tilly, H. (2011). Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet Oncology, 12(5), 460–468. doi:10.​1016/​S1470-2045(11)70069-9.
113.
114.
Tilly, H., Lepage, E., Coiffier, B., Blanc, M., Herbrecht, R., Bosly, A., … Reyes, F. (2003). Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 102(13), 4284–4289. doi:10.​1182/​blood-2003-02-0542.
115.
Abramson, J.S., Hellmann, M., Barnes, J.A., Hammerman, P., Toomey, C., Takvorian, T., … Hochberg, E.P. (2010). Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer, 116(18), 4283–4290. doi:10.​1002/​cncr.​25278.
116.
Ferreri, A.J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G.A., Frezzato, M., … Cavalli, F. (2009). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. The Lancet, 374(9700), 1512–1520. doi:10.​1016/​S0140-6736(09)61416-1.
117.
118.
Moskowitz, C. H. (2012). Interim PET-CT in the management of diffuse large B-cell lymphoma. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2012(1), 397–401. doi:10.​1182/​asheducation-2012.​1.​397.
119.
Awan, U., Siddiqui, N., SaadUllah, M., Bashir, H., Farooqui, Z. S., Muzaffar, N., & Mahmmood, M.T. (2013). FDG-PET scan in assessing lymphomas and the application of Deauville Criteria. JPMA. The Journal of the Pakistan Medical Association, 63(6), 725–30. Retrieved from http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23901673.
120.
121.
Kewalramani, T., Zelenetz, A.D., Nimer, S.D., Portlock, C., Straus, D., Noy, A., … Moskowitz, C.H. (2004). Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 103(10), 3684–3688. doi:10.​1182/​blood-2003-11-3911.
122.
Gisselbrecht, C., Glass, B., Mounier, N., Gill, D.S., Linch, D.C., Trneny, M., … Schmitz, N. (2010). Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28(27), 4184–4190. doi:10.​1200/​JCO.​2010.​28.​1618.
123.
Glass, B., Hasenkamp, J., Wulf, G., Dreger, P., Pfreundschuh, M., Gramatzki, M., … Schmitz, N. (2012). Oral Abstract Session , Sat, 3 : 00 PM-6 : 00 PM High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma : results of a prospective study of the German high-grade non-H. Journal of Clinical Oncology, Retrieved from http://​meetinglibrary.​asco.​org/​content/​99784-114.
124.
El Gnaoui, T., Dupuis, J., Belhadj, K., Jais, J.P., Rahmouni, A., Copie-Bergman, C., … Haioun, C. (2007). Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Annals of Oncology, 18(8), 1363–1368. doi:10.​1093/​annonc/​mdm133.
Metadata
Title
The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review
Authors
Fernando Mendes
Cátia Domingues
Ricardo Teixo
Ana Margarida Abrantes
Ana Cristina Gonçalves
Inês Nobre-Gois
Miguel Jacobetty
Ana Bela Sarmento
Maria Filomena Botelho
Manuel Santos Rosa
Publication date
01-09-2015
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-015-9581-1

Other articles of this Issue 3/2015

Cancer and Metastasis Reviews 3/2015 Go to the issue

Clinical

Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer

Clinical

Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials

Clinical

Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma

Clinical

Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis

Clinical

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications

Clinical

Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits